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Summary
Objective: To study the association between the preoperative value of serum HE4 marker and poor histological prognostic factors
depending on the subtype of endometrial cancer (EC): endometrioid and non-endometrioid tumors. Methods: Prospective and multicenter
cohort study including patients with EC in Miguel Servet University Hospital of Zaragoza (Spain) and Hospital Clínico San Carlos
of Madrid (Spain) from January 2017 to March 2020. Preoperative serum levels of HE4 were analyzed by clinical and pathological
characteristics. Results: Overall, 190 patients were included. Of them, 158 were subtype I of EC and 32 were subtype II tumors. In
endometrioid EC, a statistically significant association was found between the preoperative HE4 value and tumor size (p < 0.001),
deep myometrial invasion (p = 0.001), lymphovascular space invasion (LVSI) (p = 0.002), cervical (p = 0.001), adnexal (p = 0.023),
isthmus (p < 0.001) and parametrial involvement (p = 0.012), lymph node metastasis (p = 0.025) and FIGO stage (p < 0.001). On the
contrary, no histological factors showed statistical association except LVSI (p = 0.025) in the non-endometrioid subtype. Conclusions:
The preoperative value of HE4 is related differently with several established prognostic factors for EC according to the histological type
of tumor. These results could be relevant in order to standardize a prognostic value of HE4 in EC.
Key words: HE4; Endometrioid endometrial cancer; Serous endometrial cancer; Clear cells endometrial cancer.
Introduction
Endometrial cancer (EC) is the most common gyneco-
logical malignancy in developed countries and its incidence
is increasing year-by-year [1].
The endometrioid subtype, also known as subtype I, is
the most common and is the best prognostic subtype, as it is
usually diagnosed at an early stage, low grade and with su-
perficial myometrial invasion. The non-endometrioid sub-
type, or subtype II, includes especially uterine serous can-
cer (USC) and clear-cell carcinoma (CCC). These subtypes
show a more aggressive development and they are associ-
ated with a higher risk of recurrence, and despite its low
prevalence, they account for the majority of deaths related
to uterine cancer [2, 3].
HE4 is a recent application tumor marker, described by
first time in 1991 by Kirchhoff et al. whose utility has
been demonstrated in the diagnosis and monitoring of ovar-
ian cancer with the Risk of Ovarian Malignancy Algorithm
(ROMA) [4]. However, there is increasing evidence of its
possible application in EC. Currently, there is no consensus
on the possible application of HE4 as a preoperative marker
for EC. However, there seems to be a correlation between
EC prognostic factors and preoperative HE4 levels [5].
The aim of the present study is to explore if the HE4
marker is related to histological prognostic factors of EC
by histologic subtype.
Methods
We conducted a prospective and multicenter study in a
cohort of patients diagnosed of EC at two medical centers in
Spain: “Hospital Universitario Miguel Servet” in Zaragoza
and “Hospital Clínico San Carlos” in Madrid, from January
1st, 2017 to March 1st, 2020. In both Centers EC is man-
aged following the same clinical guidelines and protocols.
In the period under review, 208 patients diagnosed and
treated of EC had a preoperative determination in serum of
HE4. Blood samples were collected within 2 weeks before
planned surgery. Serum was stored at -80 ◦C until analysis
in routine clinical laboratory of both hospitals. This study
used the serum HE4 electrochemiluminiscent kits Cobas
e411 (Roche Diagnostics®). Women with pleural effu-
sion, hepatic failure or renal insufficiency were excluded
due to possible interference with HE4 values. Patients
diagnosed with other histological subtypes, synchronic or
metachronous tumors or who had received neoadjuvant
treatments were also excluded.
In all cases, HE4 was assessed in serum preoperatively.
All patients underwent hysterectomy and salpingoophorec-
tomy. Pelvic, or pelvic and para-aortic lymphadenectomy
(LDN) was performed following guidelines of the Span-
ish Society of Gynecology and Obstetrics and the European
Society of Gynecological Oncology [6, 7]. LDN was per-
formed in all subtype II cases.
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Wecarried out two comparative groups based on the clas-
sic cancer classification: subtype I included endometrioid
subtype and subtype II included USC and CCC. We stud-
ied the possible relationship of the preoperative HE4 value
depending on this classification.
All postoperative specimens were studied by at least
two pathologists specialized in oncological gynecology and
when controversy existed, a third pathologist reviewed the
surgical sample. Patients were classified according to his-
tological FIGO grade in low-moderate grade (G1-G2) and
high grade (G3), and according to FIGO stage in early stage
(I and II) and advanced stage (III and IV). The histotype was
reviewed by at least two gynecological pathologists using
current World Health Organization criteria [8].
The present study was approved by the Research Ethics
Committee in Aragón (CEICA), with the study reference
code PI16/0252. All patients gave written informed con-
sent. The study was conducted in accordance with appli-
cable laws and regulations, including the ethical principles
contained in the Declaration of Helsinki.
Statistical analysis
Data was collected in accordance to privacy policies.
Statistics Process Social Sciences (SPSS) 22.0 for Win-
dows (Copyright© Inc., 2013) was used for further statis-
tical analysis.
For the descriptive analysis the categorical variables
were expressed with their frequencies and percentages. The
parametric distribution of the HE4 marker was studied with
the Kolmogorov-Smirnov test. The variables that did not
follow a normal distribution were expressed with the me-
dian and interquartile range (IQR) and those that present a
normal distribution were expressed in mean and standard
deviation (SD).
U Mann-Whitney test was used for the analysis of di-
chotomous qualitative variables, and Kruskal-Wallis test for
non-dichotomous qualitative ones. In all statistical tests,
p < 0.05 was considered as the reference value of signif-
icance.
Results
We included 190 patients with subtype I EC (n = 158) and
subtype II tumors (n = 32). The mean age of women at diag-
nosis was 64.8 years (SD 10.4) for subtype I and 69.1 (SD
11.6) years for subtype II. The median of the preoperative
HE4 marker variable was 72.7 pmol/L (IQR 68.6 pmol/L)
and 85.1 pmol/L (IQR 60), respectively, with no statistical
differences between the groups (p = 0.340). LDN was per-
formed in 59 patients (62.7%) with endometrioid EC and 28
patients (87.5%) with USC or CCC. The reasons for not per-
forming LDN in these cases were advanced age and coexis-
tence of severe medical comorbidities that significantly in-
creased the surgical risk. The demographic and histological
characteristics depending on the subtype of EC are shown
in Table 1.
We performed an analysis to study the relationship be-
tween HE4 preoperative value and the histological risks fac-
tors for EC. In endometrioid EC group, the preoperative
value of HE4 marker was associated with all studied histo-
logical prognostic factors, finding a statistically significant
association with all of them. However, in subtype II g, only
lymphovascular space invasion (LVSI) was significantly as-
sociated with the preoperative HE4 value (p = 0.025). The
rest of the studied histological factors did not show a sta-
tistically significant association with the preoperative HE4
value in this group. This data is shown in Table 2.
Discussion
In our sample, the preoperative value of HE4 in subtype
I of ECwas correlated with all studied histological prognos-
tic factors: a higher HE4 marker value was associated with
poor histological prognostic factors. However, in subtype
II of EC, preoperative HE4 value only showed statistical
association with LVSI. Thus, we think that the HE4 serum
levles must be interpreted differently for endometrioid and
non-endometrioid EC.
The classic dualistic classification proposed by
Bokhman in 1983 is still in use today [9]. Following
this classification, there are two different histological
types of endometrial tumors, with different behavior and
prognosis. Histological features are also different between
them. Thus, type II tumors can have an aggressive behavior
without being associated with other histological classic
factors of poor prognosis. Conversely, this is not the
case in subtype I, in which histological factors are usually
correlated especially in well or moderately differentiated
tumors [3, 10].
The significance of the HE4 marker in EC has been less
studied than in other types of tumors such as ovarian cancer
[4, 11-13]. There are few studies that analyze the relation-
ship of serumHE4marker with histological risk factors, and
their results are heterogeneous. They do not usually take
into account the differences in behavior of both tumors re-
ported by the dualistic classification. To date, this is the first
study comparing the significance of preoperative HE4 in EC
based on the histological subtype.
Bignotti et al. studied the relationship between HE4 and
the clinic-pathological features in 138 patients with EC and
found out that HE4 serum levels were significantly associ-
ated with several variables of poor prognosis: myometrial
invasion, LVSI, cervical and adnexal involvement, lymph
node status and FIGO stage. There was no difference in
HE4 value between the endometrioid (n = 109) and non-
endometrioid subtype (n = 29) groups. The authors demon-
strated for the first time that high HE4 preoperative levels
may identify patients harboring a more aggressive EC phe-
notype [14]. One year later, Zanotti et al. reached a very
similar conclusion, but only 15 cases of serous carcinoma
and clear cells were included in their study [15]. None of
them studied whether the association showed between HE4
and histological factors was different when the analysis was
performed taking into account the histological EC subtype.
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Table 1. — Demographic and histological features in endometrioid and non-endometrioid EC groups.
Endometrioid Non-endometrioid
n (%) n (%)
Parity
Nulliparous 35 (22.2) 8 (25)
< 3 birth 89 (56.3) 14 (43.7)
≥ 3 births 34 (21.5) 10 (31.3)
Arterial hypertension 87 (55.1) 13 (40.6)
Diabetes Mellitus 33 (20.9) 5 (15.6)
Menopausal status 139 (88) 30 (93.8)
Obesity
BMI∗ < 25 63 (39.9) 12 (37.5)
BMI∗ 25-40 77 (48.7) 20 (62.5)
BMI∗ > 40 18 (11.4) 0
Tumor size < 20 mm 55 (34.8) 10 (31.2)≥ 20 mm 103 (65.2) 22 (68.8)
Histological grade High grade (G3) 23 (14.6) 32 (100)Low grade (G1-G2) 135 (85.4) 0
Myometrial invasion
No invasion 27 (17.1) 4 (12.5)
Invasion < 50 % 82 (51.9) 14 (43.8)
Invasion > 50% 49 (31.1) 14 (43.8)
Lymph-vascular space invasion Presence 13 (8.2) 11 (34.4)Absence 145 (9.2) 21 (65.6)
Histological subtype
Endometrioid 158 (100) 0
Serous 0 27 (84.4)
Clear cell 0 5 (15.6)
FIGO stage I-II 144 (91.1) 18 (56.3)III-IV 14 (8.9) 14 (43.7)
Lymphatic node involvement Presence 8 (5.3) 10 (31.2)Absence 150 (94.7) 22 (68.8)
Uterine isthmus involvement Presence 19 (12) 4 (12.5)Absence 139 (88) 28 (87.5)
Adnexal involvement Presence 6 (3.8) 5 (15.6)Absence 152 (96.2) 27 (84.4)
Uterine cervical involvement Presence 11 (7) 5 (15.6)Absence 147 (93) 27 (84.4)
Parametrial involvement Presence 4 (2.5) 4 (12.5)Absence 154 (97.5) 28 (87.5)
∗BMI (Body Mass Index).
Other subsequent studies have reviewed the correlation
between HE4 and several histological prognostic factors
[16-20]. One of the most important is the study by Wang
et al. which included 258 patients. A correlation of the
marker with histological factors of poor prognosis was ob-
served again. However, in this notable study, the histologi-
cal type of tumors was not reported [16]. Other studies in-
cluded exclusively endometrioid tumors showing the prog-
nostic significance of HE4 value in this group [17, 18].
In our study, there were no significant differences in the
HE4 value based on the histological subtype. This result is
consistent with other previous studies [14, 15, 19, 21] and
implies that its preoperative absolute value is not an accu-
rate tool to differentiate the histological type of the tumor.
These do not negate our finding that the HE4 value must be
interpreted differently between the two classic types of EC.
The correlation between preoperative HE4 levels and the
FIGO stage has been studied in the literature. The majority
of studies analyze the differences between early (I-II) and
advanced (III-IV) stages, however, some authors make al-
ternative comparisons [14, 16, 22]. Therefore, the results
when analyzing the possible association between the HE4
marker and the stage are heterogeneous and difficult to com-
pare.
Li et al. studied the risk factors of node metastasis from
the clinicopathological characteristics and preoperative lab-
oratory results of 393 patients surgically staged with EC
[23]. The majority (84.2%) was subtype I of EC. Higher
preoperative levels of serum HE4 (OR 4.25, 95% CI 1.65-
10.94, p = 0.003), and non-endometrioid histology (OR
16.64, 95% CI 5.96-46.47, p < 0.001) were independent
risks factors for pelvic lymphatic metastasis in EC. The au-
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Table 2. — Statistical analysis of the relationship of HE4 marker with prognostic factors in endometrioid and
non-endometrioid EC groups.
Endometrioid HE4
p value Non-endometrioid HE4 p value
Median (IQR)* Median (IQR)*
Tumor size < 20 mm 55.5 (35.6) < 0.001 57.9 (55.6) 0.096≥ 20 mm 86.4 (80.6) 97.1 (96.9)
Myometrial invasion
No invasion 45.3 (16)
< 0.001
81.6 (47.5)
0.508Invasion < 50 % 69 (50.9) 65.6 (56.8)
Invasion > 50% 105.3 (98.1) 95.3 (99.5)
Lymph-vascular space invasion Presence 152 (183.9) 0.002 115.4 (117.7) 0.025Absence 68.5 (57.3) 76.1 (42.6)
FIGO stage I-II 69 (57.5) < 0.001 61.3 (54.1) 0.071III-IV 119.4 (253.4) 98 (325.2)
Lymphatic node involvement Presence 144.1 (296.3) 0.025 102.5 (76.3) 0.114Absence 70 (59.6) 75.1 (50.7)
Uterine isthmus involvement Presence 148.3 (240) < 0.001 77 (50.5) 0.345Absence 68.5 (53.2) 130 (265.5)
Adnexal involvement Presence 105.9 (388.8) 0.023 88.1 (53.5) 0.749Absence 70.6 (60.8) 75.1 (203.4)
Uterine cervical involvement Presence 148.3 (287.7) 0.001 79.6 (50.6) 0.579Absence 69.5 (56.8) 150 (117.9)
Parametrial involvement Presence 210.6 (733.2) 0.012 77 (51) 0.305Absence 71.3 (62.6) 101.7 (243.2)
*IQR: interquartile range.
thors proposed a cut-off point for all cases of EC (≥ 132
pmol/L) with a high sensitivity for the detection of lym-
phatic metastases. But no distinction wasmade based on the
histological EC subtype, despite being independent factors
in the statistical analysis. As we have shown in our study,
the preoperative HE4 value does not have the same clinical
significance in subtype I and II of EC. Therefore, we think
that it might be more appropriate to propose a different cut-
off point for each subtype.
LVSI is considered one of the first steps of metastatic
spread in EC, and it is an important prognostic factor of re-
currence and survival [24]. In the last European consen-
sus conference on EC, LVSI was agreed to be an important
risk factor that can be utilized to define new risk groups and
guide adjuvant therapy use. However, this is only applica-
ble to well or moderately differentiated tumors, not to high
grade EC [25]. A small number of studies show a significant
association between the presence of LVSI and HE4 marker
increase [14, 26, 27]. Curiously, in our study it was the only
histological factor related to HE4 in both types of tumors.
Currently, this finding does not seem to have an impact on
clinical management in this subgroup, because all cases are
high grade tumors. Further studies are needed to investigate
whether higher HE4 value might be useful to differentiate a
more aggressive subgroup within type II of EC.
Two recent meta-analysis studied the value of HE4
marker in the diagnosis and prognosis of EC [28, 29]. In the
first one, 6 studies with a total of 781 patients with EC were
included, but with a limited number of non-endometrioid
cases. The results suggested that expression of HE4 was
associated with a worse prognosis in patients with EC. In
the second, the authors suggested that serum HE4 is gener-
ally an accurate tool in EC diagnosis, but with differences
depending on the histological type.
Therefore, it has been shown that the value of the pre-
operative HE4 marker has an important prognostic signifi-
cance in EC. However, it is not verified if it has the same
meaning depending on the type of tumor. Based on our re-
sults, we believe that there are important differences in the
association of HE4 with well-established histological risk
factors for EC according to the histological type.
Our main limitation is the sample size of subtype II, only
28 cases. This implies that at the moment these results
should be taken with caution. The authors assume that per-
haps a larger sample in this group could draw different con-
clusions. More studies with a larger sample are needed to
verify these findings and to establish if a different cut-off
point associated to prognostic value is necessary depending
on the type of tumor.
Conclusions
Preoperative value of HE4 is related differently to histo-
logical prognostic factors for EC depending on the histolog-
ical type of tumor. While in endometrioid subtype, higher
HE4 preoperative value is related to multiple histological
factors of poor prognosis, in non-endometrioid subtype, it
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is only related to LVSI. These results can be very rele-
vant/significant in order to standardizethea prognostic value
of HE4 in EC, which probably is different depending on the
histological subtype. Further studies with a larger sample,
especially with more non-endometriod subtype cases, are
needed to verify these findings.
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